As science marches on, athletes and coaches march close behind. Researchers have long been interested in how red cell mass and blood volume affect exercise capacity. Interest in blood doping soared after the 1968 Mexico City Olympics. Studies in the 1970s and 1980s suggested that transfusing red cells could speed endurance performance. Diverse athletes of the time were accused of blood doping. In the late 1980s, recombinant human erythropoietin (EPO) began to supplant transfusion for doping. EPO use is a suspect in nearly 20 deaths in 4 years in European cyclists. In the 1998 Tour de France, a team was ejected for using EPO and six other teams quit the race. The beat goes on; in recent years, diverse endurance and sprint athletes have been caught or accused of using EPO. Tests to detect EPO are improving but are not yet foolproof. As EPO tests improve, blood transfusion is back in vogue and some athletes may have infused artificial blood. Tests for detecting artificial blood also exist, but it seems it will take widespread, year-round, unannounced, out-of-competition testing and stern penalties to deter blood doping.
KeywordsOxygen Carrier Hydroxyethyl Starch Recombinant Human Erythropoietin Blood Doping Olympic Winter Game
- 1.Eichner ER. Better dead than second. J Lab Clin Med 1992; 120: 359–60Google Scholar
- 2.Eichner ER. Blood doping: results and consequences from the laboratory and the field. Phys Sportsmed 1987; 15 (1): 121–9Google Scholar
- 3.Elblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion. J Appl Physiol 1972; 33: 175–80Google Scholar
- 5.Birkeland KI, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 1999; 32: 1238–43Google Scholar
- 7.Eichner ER. Finding a way: rationalizing erythropoietin in sports. Sports Med Digest 2002; 24 (6): 61–3Google Scholar
- 8.Parisotta R, Wu M, Ashenden MJ, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001; 86: 128–37Google Scholar